MedCity News September 2, 2024
As RNA biology and RNA therapeutics emerge in the mainstream of pharma, RNA foundation models offer massive potential for revolutionizing R&D.
It’s no surprise that pharma research and development (R&D) remains one of the most important hubs for innovation. Every pharma company invests heavily in and relies on R&D teams to create new therapeutics to help the company grow and profit. From 2012 to 2022, inflation-adjusted industry R&D spending increased 44 percent, from about $170 billion to $247 billion. Despite this investment, the number of US novel drug approvals remained flat at an average of 43 per year. Productivity challenges have come to the forefront as pharma companies seek to leverage every available resource.
Changing role of AI
As...
Today's Sponsors
Today's Sponsor